Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Abivax reports loss per share of $1.71 in quarter ended June 30, 2026

Abivax released results for the quarter ended June 30, 2026, reporting a loss per share of $1.71. In the same quarter a year earlier, the loss was $0.86 per share. The stock fell by around 4.5%. » More on finanzen.net
Abivax to release quarterly results for period ended 30 June 2026 on 21 September 2026

Abivax will publish its balance sheet for the quarter ended 30 June 2026 on 21 September 2026. Six analysts expect on average a loss per share of -0.917 USD (prior year -0.860 USD). Seven analysts forecast revenue of around 0.8 million USD versus 0.0 million USD in the year-ago quarter. For the current fiscal year analysts see on average a loss per share of -3.762 USD (prior year -5.450 USD) and annual revenue of 4.4 million USD on average. » More on finanzen.net
Abivax publishes quarterly results for 30.06.2026, analysts see another loss

Abivax will present the quarterly results for the period ending 30.06.2026 on 21.09.2026. Six analysts expect a quarterly loss per share of -0.801 EUR (previous year: -0.760 EUR) and seven analysts estimate revenue of 0.7 million EUR (previous year: 0.0 million EUR). For the fiscal year, 14 analysts on average forecast a loss per share of -3.291 EUR (previous year: -4.830 EUR) with average revenue of 3.8 million EUR (previous year: 0.0 million EUR). » More on finanzen.net

Financials

In the last quarter, Abivax had revenue of -€2.02m and net profit of -€235.32m

(EUR)	December 2025	YoY
Revenue	-2.02m	-
Gross profit	-3.09m	-
Net profit	-235.32m	-
EBITDA	-155.96m	-

Fundamentals

Metric	Value
Market capitalization	€6.88bn
Number of shares	87.55m
52-week high/low	€139.00 - €5.68
Dividends	No
Beta	-0.21
P/E ratio	-16.71
PEG ratio	0.30
P/B ratio	17.11
P/S ratio	-3,405.19

Company profile

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.